Immune-related hepatitis and HLA-DQB1*06:01 as potential predictor biomarkers in East Asian patients with lung cancer treated with ICIs: a large-scale real-world study
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e015197
DOI: 10.1136/jitc-2026-015197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.11.2026. Verfasst von Huan Yan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Early Clinical Trial Center, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changs…. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune-related hepatitis (IRH) and pneumonitis (IRP) occur more frequently in East Asian versus European patients receiving immune checkpoint inhibitors (ICIs). Human leukocyte antigen (HLA) allelic variations, which differ substantially between ancestries, have been associated with immune-related adverse events (irAEs) risk and ICI efficacy in European cohorts, but large-scale validation in Asian populations is lacking. Clarifying these ancestry-specific biomarkers is critical for advancing precision immunotherapy.
Methods
We conducted a single-center retrospective study of 3261 East Asian patients with lung cancer treated with ICIs (2018–2023). Of these, 380 patients developed IRH and 248 developed IRP. Each case group was randomly matched 1:3 with controls without that irAE (IRH: 1,140; IRP: 744), resulting in 1793 patients for HLA genotyping. Time-varying Cox models and landmark analyses assessed irAE-overall survival (OS) associations, adjusting for immortal time bias and clinical covariates. Sample weighted Cox-proportional hazard models were conducted to estimate the associations of HLA alleles with the occurrence of irAE and survival.
Results
With a median follow-up of 24.9 months (range 0.2–90 months), we identified two independent predictive factors: (1) Mild IRH (grade 1–2) was significantly associated with prolonged OS (p=0.004), with a median onset time of 2.17 months. This association remained consistent across landmark analyses at 3, 6, 9, 12 months and median onset time, supporting its predictive value. (2) HLA-DQB1*06:01 was independently associated with poorer OS (p=0.0004, false discovery rate: 0.03), an effect observed regardless of IRH occurrence. Notably, HLA-DQB1*06:01 frequency in our cohort (8.5%) was substantially higher than reported in European ancestry (0.7%), consistent with known ethnic differences in HLA architecture. In contrast, we found no significant associations between HLA variants and the risk of developing IRH or IRP, suggesting that HLA’s predictive impact operates through mechanisms distinct from irAE susceptibility.
Conclusions
This study provides the first large-scale evidence that mild IRH is an early favorable predictive indicator and HLA-DQB1*06:01 identifies a high-risk subgroup, collectively enabling actionable risk stratification in ICI-treated East Asian patients. The observed ethnic differences in HLA allele frequencies and their distinct associations with survival outcomes underscore the critical need for ancestry-informed precision oncology approaches in cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Early Clinical Trial Center, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
- School of Clinical Medicine, Qinghai University, Xining, Qinghai, China.
- Department of Dermatology, Xiangya Hospital Central South University, Changsha, Hunan, China.
- Furong Laboratory, Changsha, Hunan, China.
- College of Life Sciences, Hunan Normal University, Changsha, Hunan, China.
- Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Förderung
- F. Hoffmann-La Roche
- National Natural Science Foundation of China
Zitieren
APA
Yan, H., Zhou, G., Wu, Y., Qin, H., Huang, Z., Yang, D., Zhang, X., Zhang, Y., Xia, Y., Wu, L., Xiang, H., Chen, X., Liu, H., Xiong, W., Wang, F., Zeng, L., & Zhang, Y. (2026). Immune-related hepatitis and HLA-DQB1*06:01 as potential predictor biomarkers in East Asian patients with lung cancer treated with ICIs: a large-scale real-world study. Journal for ImmunoTherapy of Cancer, 14(11), e015197. https://doi.org/10.1136/jitc-2026-015197
Vancouver
Yan H, Zhou G, Wu Y, Qin H, Huang Z, Yang D, et al. Immune-related hepatitis and HLA-DQB1*06:01 as potential predictor biomarkers in East Asian patients with lung cancer treated with ICIs: a large-scale real-world study. Journal for ImmunoTherapy of Cancer. 2026;14(11):e015197. doi:10.1136/jitc-2026-015197
BibTeX
@article{Yan2026,
author = {Yan, Huan and Zhou, Guowei and Wu, Yiyou and Qin, Haoyue and Huang, Zhe and Yang, Dan and Zhang, Xing and Zhang, Yuda and Xia, Yang and Wu, Lin and Xiang, Hua and Chen, Xiang and Liu, Hong and Xiong, Wei and Wang, Fuyan and Zeng, Liang and Zhang, Yongchang},
title = {Immune-related hepatitis and HLA-DQB1*06:01 as potential predictor biomarkers in East Asian patients with lung cancer treated with ICIs: a large-scale real-world study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e015197},
doi = {10.1136/jitc-2026-015197}
}
EUVIMED